tailieunhanh - Báo cáo y học: "Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. | Strangfeld et al. Arthritis Research Therapy 2010 12 R5 http content 12 1 R5 RESEARCH ARTICLE Open Access Risklofincident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT Anja Strangfeld 1 Franka Hierse1 Rolf Rau2 Gerd-Ruediger Burmester3 Brigitte Krummel-Lorenz4 Winfried Demary5 Joachim Listing1 and Angela Zink1 3 Abstract Introduction We used the data of the German biologics register RABBIT a nationwide prospective cohort study to investigate the risk of new or recurrent malignancy in patients with rheumatoid arthritis RA receiving biologics compared to conventional disease modifying anti-rheumatic drugs DMARDs . Methods The analysis was based on patients with RA enrolled in RABBIT at the start of a biologic or conventional DMARD therapy between 01 May 2001 and 31 December 2006. Incidences of first or recurrent malignancies were analysed separately. A nested case-control design was used to investigate the risk of developing a first malignancy. Matching criteria were age gender follow-up time disease activity score based on 28 joint counts DAS28 at study entry smoking status and selected chronic co-morbid conditions obstructive or other lung disease kidney liver or gastrointestinal disease psoriasis . Results A prior malignancy was reported in 122 out of 5 120 patients. Fifty-eight of these patients had received anti-TNFa agents 9 anakinra and 55 conventional DMARDs at study entry. In 14 patients ever exposed to anti-TNFa eight to anakinra one 15 recurrent cancers were observed. The average time period since the onset of the first malignancy was nine years. Crude recurrence rates per 1 000 patient-years pyrs were for patients exposed to anti-TNFa agents for anakinra patients and for patients exposed to DMARDs only Incidence rate ratio anti-TNFa vs. DMARD P . . In patients without prior cancer 74 patients 70 female mean age .